BioWorld

Sep. 20, 2004

BMS Drops Flamel's Basulin; Shares Suffer 22 Percent Hit

It may be true that "two out of three ain't bad" - but two pieces of good news and one seriously negative item added up to trouble on Wall Street for Flamel Technologies SA. (BioWorld Today) Read More

Guilford Divests Biopolymer Delivery Patents To Angiotech

Serendipitous Double Knockout Sheds Light On Brain Chemistry

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 14, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...